PATENT CLAIM ANALYSIS

Application Number: 15976847
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["424", "490000"]

Abstract:
An improved microparticle or lyophilized or otherwise reconstitutable microparticle composition thereof for medical therapy, including ocular therapy.

Claim (Index 27):
The lyophilized or reconstitutable solid of aggregating microparticles of  claim 16 , wherein the therapeutic agent is selected from Tivosinib, Imatinib, Gefitinib, Erlotinib, Lapatinib, Canertinib, Semaxinib, Vatalaninib, Sorafenib, Axitinib, Pazopanib, Dasatinib, Nilotinib, Crizotinib, Ruxolitinib, Vandetanib, Vemurafenib, Bosutinib, Cabozantinib, Regorafenib, Vismodegib, and Ponatinib.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 93.0
- Lexical Diversity: 1.1875
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15349985', '15782755', '15273686', '13995727', '15782744']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7572196409364685
- 35 USC 102 Novelty (BERT): 0.5432498580234938
- Combined Prediction Score: 0.735822662645171
- Mean Citation Score: 283.64715200000006
- Max Citation Score: 399.21332
- Similarity Product: 282.00425635383607

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test